Roles of RNA m6A modification in nonalcoholic fatty liver disease

Hepatol Commun. 2023 Jan 27;7(2):e0046. doi: 10.1097/HC9.0000000000000046. eCollection 2023 Feb 1.

Abstract

NAFLD is a series of liver disorders, and it has become the most prevalent hepatic disease to date. However, there are no approved and effective pharmaceuticals for NAFLD owing to a poor understanding of its pathological mechanisms. While emerging studies have demonstrated that m6A modification is highly associated with NAFLD. In this review, we summarize the general profile of NAFLD and m6A modification, and the role of m6A regulators including erasers, writers, and readers in NAFLD. Finally, we also highlight the clinical significance of m6A in NAFLD.

Publication types

  • Review

MeSH terms

  • Humans
  • Non-alcoholic Fatty Liver Disease* / genetics
  • RNA Methylation